Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ImmuPharma says pre-clinical study points to other indications for lead drug

Currently being developed to treat lupus, peptide P140 may hold the potential to treat another painful autoimmune disease
vials be processed
The findings were encouraging for a drug that's already known to be safe and well tolerated

Pre-clinical work by ImmuPharma PLC (LON:IMM) on P140, the peptide currently being developed as Lupuzor for the treatment of people with lupus, reveals it may have other potential indications.  

The company's co-founder, Professor Sylviane Muller, and her team believe the drug could be deployed to treat an autoimmune disease called chronic inflammatory demyelinating polyneuropathy, or CIDP.

This a condition where medication is currently lacking and which is characterised by fatigue, diminished or absent tendon reflexes and sensory deficits, usually starting in the hands and feet.

CLICK HERE: For the full announcement 

The results of the pre-clinical study have been published in the Journal of Autoimmunity.

"Over the last couple of years we have provided further evidence of the role the P140 peptide can take in the potential treatment of other autoimmune diseases in addition to Lupus," said Muller.

"We are delighted that these results demonstrate positive pre-clinical data in a murine model of CIDP, which has no available disease-specific treatment.  We look forward to providing a further update on the progress of our CIDP programme in due course."

 

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

Artificial intelligence
October 29 2018
E-therapeutics believes it is now focused on the right activities
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use